Skip to content
OncLive® On Air cover art

All episodes

OncLive® On Air, 500 episodes. Page 5 of 5.

#
Title
401

S11 Ep33: Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

402

S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

403

S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

404

S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

405

S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

406

S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

407

S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

408

S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH

409

S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

410

S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

411

S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

412

S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

413

S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

414

S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

415

S11 Ep19: Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

416

S11 Ep18: Board Review Resources 2024

417

S11 Ep17: How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

418

S11 Ep16: FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma

419

S11 Ep15: Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting

420

S11 Ep14: Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

421

S11 Ep13: FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

422

S11 Ep12: Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

423

S11 Ep11: Heme & Onc Fellow Board Review Tips 2024

424

S11 Ep10: Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

425

S11 Ep9: Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

426

S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

427

S11 Ep7: Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

428

S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer

429

S11 Ep5: Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

430

S11 Ep4: Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

431

S11 Ep3: Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

432

S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

433

S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

434

S11 Ep1: Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

435

S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer

436

S10 Ep49: Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC

437

S10 Ep48: Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

438

S10 Ep47: Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer

439

S10 Ep47: Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

440

S10 Ep46: Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

441

S10 Ep45: Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

442

S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

443

S10 Ep43: Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

444

S10 Ep42: Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

445

S10 Ep41: ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer

446

S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

447

S10 Ep39: Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

448

S10 Ep38: Agulnik Highlights Key Updates in GIST Research and Management

449

S10 Ep37: Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

450

S10 Ep36: Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma

451

S10 Ep35: ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

452

S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations

453

S10 Ep34: Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

454

S10 Ep33: Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

455

S10 Ep33: Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

456

S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

457

S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa

458

S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

459

S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

460

S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

461

S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

462

S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

463

S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

464

S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

465

S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

466

S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL

467

S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management

468

S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

469

S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

470

S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

471

S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

472

S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

473

S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC

474

S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice

475

S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

476

S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference

477

S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness

478

S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

479

S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

480

S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment

481

S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma

482

S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

483

S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management

484

S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment

485

S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

486

S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management

487

S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

488

S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

489

S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL

490

S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials

491

S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

492

S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

493

S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions

494

S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

495

S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

496

S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

497

S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors

498

S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

499

S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

500

S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes